Quantcast

Latest minimal residual disease Stories

2015-01-07 12:27:37

Deal Expected to Expedite the Development and Commercialization of Immunosequencing Applications SEATTLE, Jan.

2014-12-08 20:20:25

Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif., Dec.

2014-12-07 20:21:07

- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia NORTH CHICAGO, Ill., Dec.

2014-12-06 12:21:46

78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle THOUSAND OAKS, Calif., Dec.

2014-12-02 12:31:08

Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ(TM) Test in Patients with ALL, CLL, MM, DLBCL SEATTLE, Dec.

2014-11-24 16:25:26

First available immunosequencing Kit with validated bias control methodology to ensure data reliability SEATTLE, Nov.

2014-10-09 16:27:54

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS,

2014-09-29 12:29:44

Highly distinguished advisory board to strengthen incorporation of Next Generation Sequencing (NGS) into clinical care for patients with blood cancers SEATTLE, Sept.


Word of the Day
ultimo
  • In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.
  • In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.
The word 'ultimo' comes from the Latin phrase 'ultimo mense', 'in the last month'.
Related